FIA
ZYNE

FNY Investment Advisers’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

FNY Investment Advisers’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-500
Closed -$5.77K – 1185
2019
Q1 		$2K Hold
500
– – ﹤0.01% 616
2018
Q4 		$1K Sell
500
-5,500
-92% -$30.1K ﹤0.01% 641
2018
Q3 		$48K Buy
+6,000
New +$46.1K 0.01% 375

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FNY Investment Advisers's ZYNE Position: Q2 2019 in Review

FNY Investment Advisers sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2019, closing a stake of 500 shares — an estimated $5.77K sold.

FNY Investment Advisers first reported a position in ZYNE in Q3 2018 and held it in 3 quarters. The position peaked at $48K in Q3 2018. 76 funds tracked by Wall St. Rank hold ZYNE as of Q2 2019.

  • FNY Investment Advisers reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2019 after selling out during the quarter.
  • FNY Investment Advisers sold 500 Zynerba Pharmaceuticals, Inc shares in Q2 2019, an estimated $5.77K.
  • FNY Investment Advisers first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2018 and held it in 3 quarters.
  • FNY Investment Advisers's Zynerba Pharmaceuticals, Inc position peaked at $48K in Q3 2018.
  • 76 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2019.

Based on FNY Investment Advisers's 13F filing for Q2 2019, filed 24 Jul 2019.